Establishment of novel cardiorenal linkage suppressive therapy by KATP channel opener Nicorandil

Research Project

Project/Area Number	15K09072
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Cardiovascular medicine
Research Institution	Gifu University
Principal Investigator	Nishigaki kazuhiko 岐阜大学, 大学院医学系研究科, 准教授 (60198447)
Project Period (FY)	2015-04-01 – 2018-03-31
Project Status	Completed (Fiscal Year 2017)
Budget Amount *help	¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000) Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000) Fiscal Year 2016: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000) Fiscal Year 2015: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Keywords	造影剤腎症 / ニコランジル / シスタチンＣ / 経皮的冠動脈インターベンション / 循環器内科学 / 臨床心臓学 / 造影剤腎症モデル / 慢性腎臓病 / 冠動脈疾患 / 糖尿病性腎症
Outline of Final Research Achievements	We conducted a prospective randomized trial to assess the protective effect of continuous intravenous infusion of nicorandil against contrast-induced nephropathy (CIN) in patients with poor renal function. We randomly assigned patients who would subsequently undergo elective percutaneous coronary intervention (PCI) and who had a high serum cystatin C level to a saline group or a nicorandil group. The average percent increases in serum creatinine and cystatin C following PCI were significantly smaller in the nicorandil group than the saline group, and the average percent decline in the estimated glomerular filtration rate was smaller in the nicorandil group. Correspondingly, the incidence of CIN was dramatically lower in the nicorandil group than the saline group. Univariate regression analysis revealed nicorandil treatment to be the only significant predictor of CIN development. Nicorandil strongly prevents CIN in patients with poor renal function undergoing PCI.